Navigation Links
FSU researcher's 'mutant' proteins could lead to new treatment for heart disease
Date:3/24/2008

TALLAHASSEE, Fla. -- Heart damage due to blocked arteries remains the leading cause of disease and death in the Western world, but a Florida State University College of Medicine researcher is helping to open new pathways toward treating the problem.

Michael Blaber, a professor in the department of biomedical sciences, is researching mutant forms of a human protein that have been shown to help the human body grow new blood vessels to restore blood flow in damaged areas of the heart.

Working with a $264,000, three-year grant from the American Heart Association, Blaber hopes to provide data that will enable the use of the mutant proteins in new treatment methods previously unavailable for patients with advanced no option heart disease.

This research offers the potential to treat people who currently are being sent home to die, Blaber said. Weve tested a group of mutants in the laboratory with unusual properties of increased stability and activities -- good properties. In some cases it was unexpected, but the results are very promising.

Obstructed blood vessels and clogged or blocked arteries typically are treated through angioplasty, the mechanical widening of a vessel, or bypass surgery. Some patients, however, have numerous small blockages that cannot be treated through traditional approaches. In most cases, they are sent home with a predicted life expectancy that, no matter how its phrased, sounds like a death sentence.

A new approach to the problem called therapeutic coronary angiogenesis is creating hope through the injection of human fibroblast growth factor protein into affected areas. Improvements with the procedure may arise from the use of mutant forms with increased stability.

Blaber and his research team are creating artificial mutant proteins in their College of Medicine laboratory that mimic the human proteins used in angiogenic therapy, and with enhanced stability properties. So far, the mutant proteins engineered at the College of Medicine have exhibited potency in stimulating cell growth while simultaneously maintaining greater stability under conditions common to angiogenic therapy.

The work has enormous potential commercial applications and already has drawn the attention of private companies interested in the results Blabers lab has achieved and the intellectual properties his studies are generating.


'/>"/>

Contact: Doug Carlson
doug.carlson@med.fsu.edu
850-645-1255
Florida State University
Source:Eurekalert

Related medicine news :

1. NYU dental researchers find evidence of periodontal disease leading to gestational diabetes
2. Researchers Gain Insights Into On-Off Switch for Cells
3. Molecular science could further improve leukemia survival, say St. Jude researchers
4. Stanford researchers unmask proteins in telomerase, a substance that enables cancer
5. Recognizing outstanding young researchers
6. Researchers sharpen search for new marine medicines with novel techniques
7. Global Sound Conference Brings Worlds Top Sound Researchers, Technologists and Musicians to Los Angeles for Four Day Symposium
8. Queensland researchers get the latest tools to fight cancer
9. Researchers find 1 in 6 women, 1 in 10 men at risk for Alzheimers disease in their lifetime
10. Researchers discover second depth-perception method in brain
11. Researchers study new drug and indications for heated chemotherapy treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... ... pharmaceutical inserts and outserts. As a means of expanding capabilities Flottman has ... enable Flottman to individually code professional inserts (PIs) and patient package inserts (PPIs) ...
(Date:12/9/2016)... York, NY (PRWEB) , ... December 09, 2016 , ... ... raises awareness for organ transplantation while encouraging readers to sign up as an organ ... a lifesaving organ transplant. , An organ donor can save up to 8 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... will become Quality Insights beginning January 1, 2017. The name change aligns ... commitment to measuring and improving health care quality. , “We are very proud ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The ... ultimate weight loss and wellness program, at their world headquarters of Omni La Costa ... and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, or ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... LLC announced today that Steven E. Dawson has been appointed as chief ... Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles managing and executing transformation, ... brings to the company deep operational and leadership expertise, a strong financial ...
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... travel vaccines market to grow at a CAGR of 6.83% during ... and the growth prospects of the global travel vaccines market for ... generated from the sales of various vaccines administered to actively immunize ...
(Date:12/8/2016)... 8, 2016 IRIDEX Corporation (NASDAQ: IRIX ... shares of common stock, $0.01 par value (the "Offering" with ... offering.  The final terms of the Offering will depend on ... there can be no assurance as to whether or when ... use the net proceeds it will receive from this offering ...
Breaking Medicine Technology: